NHS ENGLAND SPECIALISED SERVICES

CLINICAL PANEL REPORT

Date: September 2019

Intervention: Plerixafor

Indication: stem cell mobilisation in adults and paediatrics

ID: 1902

Gateway: 2 Round 2

Programme: Blood and Infection

CRG: Blood and Bone Marrow Transplantation

Information provided to the panel

Clinical Panel Report from Gateway 2 Round 1

Two Evidence Reviews undertaken by NICE Medicines and Technologies Programme Team

Clinical Priorities Advisory Group Summary Report

Policy Proposition

Bluteq form

Key elements discussed

This proposition is for routine commissioning. This was previously considered by the Clinical Panel in July who asked for various amendments to be made, as outlined in the previous Clinical Panel report.

It was confirmed to Panel that the amendments had been made, which could be seen from the tracked change versions of the forms presented.

The proposition states that this intervention should not be used in those patients with ‘active’ leukaemia. The evidence base for this statement was questioned. It was agreed that the wording should reflect what is stated in the Summary of Product Characteristics (SPC).

The Panel queried the recommended dosing within the proposition. In the pre-emptive section of the proposition it states 2 doses, whereas in the stopping criteria it states 3 doses. Panel were assured that this is stated in related current published clinical policies.

Progress policy development as a relative prioritisation item for May CPAG in 2020.

Recommendation

Clinical Panel recommended that this proposition progress as a for routine commissioning policy proposition.

Why the panel made these recommendations

The Clinical Panel considered that the appropriate amendments had been made as requested.

Documentation amendments required

- Remove the word ‘active’ in the exclusion criteria section of the proposition, so the proposition follows what is stated in the SPC.

Declarations of Interest of Panel Members: None.

Panel Chair: James Palmer, Medical Director

Post panel note:

The above amendment to the policy has been made in line with the requirement from Clinical Panel.